Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly those affecting children. The company has three approved medications: LIVMARLI® (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile acid synthesis disorders, and CTEXLI™ (chenodiol) for cerebrotendinous xanthomatosis. Mirum is also advancing a pipeline of investigational treatments, including Volixibat for primary sclerosing cholangitis and Fragile X syndrome, showcasing its commitment to innovative solutions in rare disease therapy.
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases and is seeking a Senior Director, Intellectual Property to lead its global IP strategy. This role involves developing and executing a comprehensive IP program, managing patent portfolio and transactional support, and providing legal advice to business development and clinical programs. The position requires a strategic and hands-on approach, balancing risk mitigation with business value.
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly those affecting children. The company has three approved medications: LIVMARLI® (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile acid synthesis disorders, and CTEXLI™ (chenodiol) for cerebrotendinous xanthomatosis. Mirum is also advancing a pipeline of investigational treatments, including Volixibat for primary sclerosing cholangitis and Fragile X syndrome, showcasing its commitment to innovative solutions in rare disease therapy.
Calico